Dudediligence.

Avalo Therapeutics, Inc

AVTXNASDAQ · Pharmaceutical Preparations
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$8,568,755

16 notices · 500,948 sh

Oct 2025 to Oct 2026

Reported ·

$6,457,706

32 sales · 0 buys

Oct 2025 to Jun 2026

The two figures cover different periods.

30 of 32 reported sales carry the 10b5-1 box. Together they are 0.62% of the shares on issue.

PLANNED · FORM 144Oct 2025 to Oct 2026REPORTED · FORM 4Oct 2025 to Jun 2026N2025DJ2026FMAMJJASO2026-08-18: CHRISTOPHER RYAN SULLIVAN, Form 1442026-08-17: MITTIE DOYLE, Form 1442026-08-17: CHRISTOPHER RYAN SULLIVAN, Form 1442026-08-17: CHRISTOPHER RYAN SULLIVAN, Form 1442026-08-11: JENNIFER RILEY, Form 1442026-08-10: MITTIE DOYLE, Form 1442026-06-02: JONATHAN GOLDMAN, Form 1442026-05-07: CHRISTOPHER SULLIVAN, Form 1442026-05-06: MITTIE DOYLE, Form 1442026-05-06: CHRISTOPHER SULLIVAN, Form 1442026-05-06: PAUL VARKI, Form 1442026-05-06: MITCHELL CHAN, Form 1442026-04-29: CHRISTOPHER SULLIVAN, Form 1442026-04-06: MITTIE DOYLE, Form 1442026-04-01: CHRISTOPHER SULLIVAN, Form 1442026-03-16: MITTIE DOYLE, Form 1442025-11-14: Goldman Jonathan, sold2026-03-16: Doyle Mittie, sold2026-04-01: Sullivan Christopher Ryan, sold2026-04-01: Doyle Mittie, sold2026-04-06: Doyle Mittie, sold2026-04-29: Sullivan Christopher Ryan, sold2026-05-05: Doyle Mittie, sold2026-05-06: VARKI PAUL, sold2026-05-06: Chan Mitchell, sold2026-05-06: Sullivan Christopher Ryan, sold2026-05-07: Sullivan Christopher Ryan, sold2026-05-15: Doyle Mittie, sold2026-05-28: Doyle Mittie, sold2026-06-23: Doyle Mittie, sold
under a no plan named▼ salesize is dollars

Form 144 notices, newest first

2026-08-18CHRISTOPHER RYAN SULLIVAN, Chief Financial Officer$622,221
31,031 shplan 2025-11-12Form 4s on file end Jun 23144 ↗
2026-08-17MITTIE DOYLE, Chief Medical Officer$98,675
5,037 shplan 2025-11-13Form 4s on file end Jun 23144 ↗
2026-08-17CHRISTOPHER RYAN SULLIVAN, Chief Financial Officer$1,385,189
70,709 shplan 2026-05-18Form 4s on file end Jun 23144 ↗
2026-08-17CHRISTOPHER RYAN SULLIVAN, Chief Financial Officer$74,762
3,749 shplan 2025-11-12Form 4s on file end Jun 23144 ↗
2026-08-11JENNIFER RILEY, Chief Strategy Officer$52,012
2,655 shplan 2025-11-12Form 4s on file end Jun 23144 ↗
2026-08-10MITTIE DOYLE, Chief Medical Officer$12,439
679 shplan 2025-11-13Form 4s on file end Jun 23144 ↗
2026-06-02JONATHAN GOLDMAN, Director$616,226
42,833 shno plan dateForm 4s on file end Jun 23144 ↗
2026-05-07CHRISTOPHER SULLIVAN, Chief Financial Officer$405,797
18,606 shplan 2025-11-12144 ↗
Form 4, 2026-05-11: sold 18,606 at $24.12 Form 4 ↗
2026-05-06MITTIE DOYLE, Chief Medical Officer$886,300
54,508 shplan 2025-11-13144 ↗
Form 4, 2026-05-19: sold 3,000 at $18.76 Form 4 ↗
2026-05-06CHRISTOPHER SULLIVAN, Chief Financial Officer$764,220
47,000 shplan 2025-11-12144 ↗
Form 4, 2026-05-07: sold 47,000 at $20.18 Form 4 ↗
2026-05-06PAUL VARKI, Chief Legal Officer$1,508,456
92,771 shplan 2025-11-12144 ↗
Form 4, 2026-05-07: sold 75,063 at $20.17 Form 4 ↗
2026-05-06MITCHELL CHAN, Director$51,495
3,167 shplan 2025-11-19144 ↗
Form 4, 2026-05-07: sold 3,167 at $22.88 Form 4 ↗
2026-04-29CHRISTOPHER SULLIVAN, Chief Financial Officer$217,527
16,915 shplan 2025-11-12144 ↗
Form 4, 2026-05-01: sold 16,915 at $13.16 Form 4 ↗
2026-04-06MITTIE DOYLE, Chief Medical Officer$1,168,608
65,800 shplan 2025-11-13144 ↗
Form 4, 2026-04-08: sold 3,970 at $18.01 Form 4 ↗
2026-04-01CHRISTOPHER SULLIVAN, Chief Financial Officer$238,268
15,959 shplan 2025-11-12144 ↗
Form 4, 2026-04-03: sold 15,959 at $16.96 Form 4 ↗
2026-03-16MITTIE DOYLE, Chief Medical Officer$466,558
29,529 shplan 2025-11-13144 ↗
Form 4, 2026-03-18: sold 25,492 at $16.15 Form 4 ↗